ASCO 2021 | PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer

Frédéric Pouliot, MD, PhD, FRCSC, University Hospital of Quebec and Laval University, Quebec City, Quebec, discusses the findings of an investigation evaluating the accuracy of PSMA-targeted PET/CT when compared to a pre-specified rigorous standard of truth including histopathology, correlative imaging or treatment response in patients enrolled in the Phase III CONDOR study (NCT03739684). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.